schizophrenia news from FierceBiotech
NewsAcadia shares plunge on mid-stage trial failure
Shares of Acadia Pharmaceuticals went into free fall this morning after the company announced that one of its schizophrenia drug candidates failed a mid-stage trial. Researchers said that ACP-104 was Read more...
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
Glutamate a big target for drug developers
The New York Times' Alex Berenson looks at the wave of new research programs focused on the neurotransmitter Read more...
Pfizer lands schizophrenia drug in $22M deal
Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front. TS-032 is an mGluR agonist, which promises to influence the Read more...
Addex gains $702M on Merck deal
Addex Pharmaceuticals was focusing on the positive this morning when it touted a $702 million pact with Merck for an experimental schizophrenia drug candidate. Merck is paying $22 million up front Read more...
ALSO NOTED: GPC Biotech's CFO resigns; Abbott Labs cuts 1,200 jobs; and much more...
> GPC Biotech's CFO Mirko Scherer has resigned; he will be replaced by Torsten Hombeck, Ph.D. Read more...
ALSO NOTED: Sucampo Pharma names new CEO; Genetic tests are going DTC at a fast pace; Panel: Give FDA power to recall; and much
> Teva and the Technion Israel Institute of Technology are exploring a pact to develop stem cell lines for research work. Read more...
Memory's Alzheimer's drug aces Phase II
Memory Pharmaceuticals has announced a positive Phase II roof-of-concept trial of MEM 3454 in 80 patients with Alzheimer's disease over an eight week treatment period. The primary endpoint of the Read more...
Schizophrenia drug gets mixed results in IIb
Forest Laboratories and Hungary's Gedeon Richter says that high doses of its antipsychotic drug failed to demonstrate a statistically significant response in a Phase IIb trial, but low doses of Read more...
ALSO NOTED: Novartis teams up with MIT; EMEA approves Galvus; and much more...
> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Read more...
| Press ReleasesPRESS RELEASE: Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal NEW YORK and BUDAPEST, Hungary, Oct. 15 -- Forest Laboratories and Gedeon Richter today announced preliminary top-line results Read more... PRESS RELEASE: Potential new drug found for schizophrenia Potential new drug found for schizophrenia PITTSBURGH, Sept. 24 U.S. researchers have developed a drug that promises to treat the cognitive deficits associated with schizophrenia. The scientists Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... PRESS RELEASE: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New approach for treatment of schizophrenia An Read more... |
Get more schizophrenia coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends